AMR SVG Icons location

Selenious AcidInjection, USP

  • Preservative free
  • Vial closure is not made with natural rubber latex
  • Single-dose vial in a concentration of 12 mcg/2 mL (6 mcg/mL) of Selenium
  • Pharmacy bulk package vial in a concentration of 600 mcg/10 mL (60 mcg/mL) of Selenium

Product Information Bulletin

Receive Availability Emails

  Pack NDC# Strength Supplied As Shelf Pack Vial Opening Size Product Info Availability

600 mcg/10 mL

Supplied As:

10 mL
Pharmacy Bulk Package Vial

NDC#: 0517-6560-05

600 mcg/10 mL

10 mL
Pharmacy Bulk Package Vial

5 20 mm Out of Stock
  • Shelf Pack 5
  • Availability Out of Stock

Wholesaler Numbers

  • ABC/SAP 10230492
  • Cardinal 5568191
  • McKesson 3988474
  • Morris & Dickson 783134

Case Information

  • Unit of Sale NDC 0517-6560-05
  • Order Size 5
  • Case Size 20
  • Case Per Tier 196

12 mcg/2 mL

Supplied As:

2 mL
Single Dose Vial

NDC#: 0517-6502-10

12 mcg/2 mL

2 mL
Single Dose Vial

10 13 mm In-Stock Shipping Weekly
  • Shelf Pack 10
  • Availability In-Stock Shipping Weekly

Case Information

  • Unit of Sale NDC 0517-6502-10
  • Order Size 10
  • Case Size 100
  • Case Per Tier 420

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent® database, please submit a message request to

For intravenous use

Selenious Acid Injection is indicated in adult and pediatric patients as a source of selenium for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Important Administration Information
Pharmacy Bulk Package or Single Dose Vial: Not for direct intravenous infusion.



Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation.
Vein Damage and Thrombosis: Selenious Acid Injection has a low pH and must be prepared and used as an admixture in PN solutions. Solutions with osmolarity of 900 mOsm/L or more must be infused through a central venous catheter.
Aluminum Toxicity: Selenious Acid Injection contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum.
Monitoring and Laboratory Tests: Monitor selenium concentrations, fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters throughout treatment.

No selenium-related adverse reactions have been reported in clinical studies or postmarketing reports in patients receiving intravenously administered PN solutions containing selenious acid within the recommended dosage range.

Pregnancy: Risk Summary: Administration of the recommended dose of Selenious Acid Injection in PN is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Lactation: Risk Summary: Selenium is present in human milk. There is no information on the effects of selenious acid on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Selenious Acid Injection and any potential adverse effects on the breastfed infant from Selenious Acid Injection or from the underlying maternal condition.

Pediatric Use: Safety and dosing recommendations in pediatric patients are based on clinical experience.

Geriatric Use: Dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

For additional safety information, please see Full Prescribing Information.

You are encouraged to report Adverse Drug Events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting or calling 1-800-FDA-1088.

REF-1167  10/2021